ElevateBio Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Private

  • Employees
  • 468

Employees

  • Latest Deal Type
  • Series D

  • Latest Deal Amount
  • $401M

  • Investors
  • 20

ElevateBio General Information

Description

Operator of a portfolio of cell and gene therapy companies intended to develop, manufacture, and commercialize life-transforming medicines. The company's business involves creating a portfolio of companies through partnerships with innovative scientists and inventors, as well as a centralized facility that integrates all the elements that translate cell and gene therapy research and development into commercially viable therapies efficiently, enabling patients to get medical products to treat severe diseases.

Contact Information

Website
www.elevate.bio
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 225 Wyman Street
  • Waltham, MA 02451
  • United States
+1 (617)
Primary Industry
Discovery Tools (Healthcare)
Vertical(s)
Life Sciences
Corporate Office
  • 225 Wyman Street
  • Waltham, MA 02451
  • United States
+1 (617)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

ElevateBio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC (Series D) 24-May-2023 $401M Completed Generating Revenue
3. Later Stage VC (Series C) 15-Jan-2021 Completed Generating Revenue
2. Early Stage VC (Series B) 12-Mar-2020 $193M $343M Completed Generating Revenue
1. Early Stage VC (Series A) 13-May-2019 $150M $150M Completed Generating Revenue
To view ElevateBio’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

ElevateBio Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a portfolio of cell and gene therapy companies intended to develop, manufacture, and commercialize life-tran
Discovery Tools (Healthcare)
Waltham, MA
468 As of 2024

Rockville, MD
 

Somerville, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

ElevateBio Competitors (18)

One of ElevateBio’s 18 competitors is Regenxbio, a Formerly VC-backed company based in Rockville, MD.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Regenxbio Formerly VC-backed Rockville, MD
Genetix Biotherapeutics Private Equity-Backed Somerville, MA
Renova Therapeutics Venture Capital-Backed Carlsbad, CA
Minoryx Venture Capital-Backed Barcelona, Spain
Verge Labs Venture Capital-Backed San Francisco, CA
You’re viewing 5 of 18 competitors. Get the full list »

ElevateBio Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

ElevateBio Investors (20)

Investor Name Investor Type Holding Investor Since Participating Rounds
Lee Family Office Family Office Minority
Novo Nordisk Corporation Minority
Woodline Partners Hedge Fund Minority
Fidelity Management & Research Company Asset Manager Minority
GG 1978 Venture Capital Minority
You’re viewing 5 of 20 investors. Get the full list »

ElevateBio Investments & Acquisitions (3)

ElevateBio’s most recent deal was a PIPE with AlloVir for . The deal was made on 26-Jul-2022.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
AlloVir 26-Jul-2022 PIPE Biotechnology
Abata Therapeutics 23-Jun-2021 Early Stage VC Drug Discovery
LifeEDIT Therapeutics 16-Nov-2020 Merger/Acquisition Drug Discovery
To view ElevateBio’s complete investments and acquisitions history, request access »

Ready to get started?

Request a free trial

ElevateBio FAQs

  • When was ElevateBio founded?

    ElevateBio was founded in 2017.

  • Where is ElevateBio headquartered?

    ElevateBio is headquartered in Waltham, MA.

  • What is the size of ElevateBio?

    ElevateBio has 468 total employees.

  • What industry is ElevateBio in?

    ElevateBio’s primary industry is Discovery Tools (Healthcare).

  • Is ElevateBio a private or public company?

    ElevateBio is a Private company.

  • What is ElevateBio’s current revenue?

    The current revenue for ElevateBio is .

  • How much funding has ElevateBio raised over time?

    ElevateBio has raised $1.27B.

  • Who are ElevateBio’s investors?

    Lee Family Office, Novo Nordisk, Woodline Partners, Fidelity Management & Research Company, and GG 1978 are 5 of 20 investors who have invested in ElevateBio.

  • Who are ElevateBio’s competitors?

    Regenxbio, Genetix Biotherapeutics, Renova Therapeutics, Minoryx, and Verge Labs are some of the 18 competitors of ElevateBio.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process